- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04670991
Evaluation of ExacTrac® Imaging Device for Repositioning Quality of Patients Undergoing an External ENT Radiotherapy (ST-IGRT-ORL)
Evaluation of the ExacTrac® Imaging Device for the Repositioning Quality of Patients Undergoing an External ENT Radiotherapy
Monocentric, category 2 study according to Jardé Law (minimal risks and constraints) of three prospective cohorts: Tumors located at the oropharynx, the oral cavity and the larynx-hypopharynx.
The main objective is to evaluate the 3D vector of the absolute residual positioning error observed with the CBCT reference imaging, after repositioning performed with ExacTrac®.
The secondary objectives are to evaluate: 1) the rate of residual errors ≥2mm (translations in all directions) and ≥2 ° (rotations in all directions) on CBCT imaging after repositionning with the ExacTrac® system; 2) the Evaluation of intrafraction movements amplitude by analyzing the ExacTrac® images taken during the irradiation; 3) the evolution of the relative position of the volume of the tumor at high risk of recurrence (CTVTHR) in relation to the spine over the entire duration of the treatment; 4) the impact of patient's weight loss, the advancement of RT and the realization of a chemotherapy / targeted therapy concomitant with RT, on the evolution of the relative position of the CTVTHR in relation to the column vertebral; 5) the dosimetric consequence of a strict bone registration on the CTVTHR coverage by calculating the post-treatment dose on the CBCT imaging.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The radiotherapy treatment preparation requires performing a dosimetric scanner (CT) of the patient in the treatment position, with the compression. The repositioning of the ENT sphere can be complex, especially in cases where there is irradiation of the supraclavicular lymph node areas. Indeed, the height of the irradiated area can easily exceed 20cm and it is necessary to ensure a good reproducibility of the repositioning of the spine relative to the skull.
At the end of the dosimetric CT, the radiotherapist delineates the macroscopic tumor volume (GTV) as well as the clinical tumor target volumes (CTVT) and lymph nodes (CTVN), which take into account the infiltration risks of the tissue around the macroscopic tumor. Margins around the VCTs then make it possible to obtain the estimated PTV target volumes (T and N), defined so that the VCTs receive the prescribed dose despite the geometric uncertainties associated with the treatment. Contours of organs at risk (OAR) are also carried out on the dosimetric CT. Margins around the most critical OARs (eg: marrow, brainstem, chiasma and optic nerves) are then added to generate predictive target volumes of organs at risk (PRV), taking into account the geometric uncertainties. These uncertainties are separated into errors in the treatment execution (random) and errors in the treatment preparation (systematic).
Execution errors include repositioning errors, organ movements (overnight), patient anatomical changes, intrafraction movements.
Errors related to treatment preparation include repositioning errors related to patient's skin spotting of the treatment isocenter during the dosimetric CT (thanks to room lasers), errors related to the CT acquisition that sets the CTV in a given position, the CTV delineation errors.
Dosimetry is then carried out taking into account the dose criteria to be respected on the PRVs and PTVs. Whatever the protocol used [Shrinking Action Level (SAL), non-action-level (NAL) or e-NAL (extented NAL)], it must at least make it possible to guarantee that the delivered dose complies with the planned dose. An optimization of the imaging protocol must then be able to reduce the margins without compromising the treatment quality, while reducing its toxicity for the patient.
On the Centre Léon Bérard accelerators equipped with both CBCT and ExacTrac®, we would like to assess the possibility of replacing or reducing the frequency of CBCTs using ExacTrac®. The time-consuming and irradiating characteristics of CBCT encourage to propose this study, which will define the patients for whom the use of CBCT can be minimized.
In addition, if the correlation between ExacTrac® and CBCT is good, the use of ExacTrac® will make it possible to control and correct intrafraction movements, and therefore reduce the random uncertainties associated with carrying out the treatment.
The possibility of using ExacTrac® imaging for the repositioning of patients treated with RCMI ENT would allow a reduction in treatment time and therefore less discomfort for the patient, a reduction in the dose linked to repositioning imaging, follow-up and correction of patient movements during the irradiation period.
Finally, this project will enable to propose new pre-treatment imaging strategies and personalized margins according to the position of the lesions to be treated at the ENT level in order to reduce the session time when possible, and to reduce the radiation doses. X due to imaging.
The overall objective is to improve the care and quality of treatment for the patient.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: BOISBOUVIER Sophie
- Phone Number: +33 4.78.78.07.98
- Email: sophie.boisbouvier@lyon.unicancer.fr
Study Locations
-
-
-
Lyon, France, 69008
- Recruiting
- Centre Leon Berard
-
Contact:
- Sophie BOISBOUVIER
- Email: sophie.boisbouvier@lyon.unicancer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Patient requiring an ENT radiotherapy with intensity modulation (IMR) in the oropharynx, oral cavity, hypopharynx or larynx with bilateral irradiation of the lymph node areas
- Treatment planned on an accelerator equipped with a CBCT and the ExacTract® device
- Patient affiliated to a social security system
- Informed consent dated and signed
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Patient under totorship, curatorship or legal protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: EXATRAC imaging
For each radiotherapy session, patient will first have an Exatrac imaging and then a CBCT imaging.
Patient's repositionning will be performed accoding to CBCT data
|
Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Verification of the feasibility of using the ExacTrac® system as a replacement for CBCT imaging for pre-treatment repositioning of ENT sphere cancers in adult patients receiving CRMI on a linear accelerator equipped with 2 modalities
Time Frame: Until the end of the radiotherapy treatment
|
3D vector of the absolute residual positioning error observed with the CBCT reference imaging, after repositioning performed with ExacTrac®
|
Until the end of the radiotherapy treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of residual errors rates ≥2mm (translations in all directions) and ≥2 ° (rotations in all directions) on CBCT imaging after repositionning with the ExacTrac® system
Time Frame: Until the end of the radiotherapy treatment
|
Percentage of differences in translations and rotations >2mm and 2 ° between the 2 systems
|
Until the end of the radiotherapy treatment
|
Evaluation of intrafraction movements amplitude by analyzing the ExacTrac® images taken during the irradiation
Time Frame: Until the end of the radiotherapy treatment
|
Average of translations and rotations obtained on the intrafraction images from ExacTrac®
|
Until the end of the radiotherapy treatment
|
Evaluation of intrafraction movements amplitude by analyzing the ExacTrac® images taken during the irradiation
Time Frame: Until the end of the radiotherapy treatment
|
Standard deviation of translations and rotations obtained on the intrafraction images from ExacTrac®
|
Until the end of the radiotherapy treatment
|
Evolution of the relative position of the volume of the tumor at high risk of recurrence (CTVTHR) in relation to the spine over the entire treatment duration
Time Frame: Until the end of the radiotherapy treatment
|
Differential 3D vector representative of the differences in translation between a bone and a soft tissue repositionning obtained during the pre-treatment repositioning correlated with the treatment progress
|
Until the end of the radiotherapy treatment
|
Evaluation of the impact of patient's weight loss on the evolution of the relative position of the CTVTHR in relation to the spine
Time Frame: Until the end of the radiotherapy treatment
|
Correlation between the 3D vector of absolute residual error and the evolution of the Body Mass Index
|
Until the end of the radiotherapy treatment
|
Evaluation of the impact of the RT progress on the evolution of the relative position of the CTVTHR in relation to the spine
Time Frame: Until the end of the radiotherapy treatment
|
Correlation between the 3D vector of absolute residual error and the treatment progress
|
Until the end of the radiotherapy treatment
|
Evaluation fo the impact of a chemotherapy / targeted therapy performed concomitantly with RT, on the evolution of the relative position of the CTVTHR in relation to the spine
Time Frame: Until the end of the radiotherapy treatment
|
Correlation between the 3D vector of absolute residual error and the administration of chemotherapy / targeted therapyconcomitantly with RT
|
Until the end of the radiotherapy treatment
|
Evaluation of the dosimetric consequence of a strict bone repositionning on the CTVTHR coverage by calculating the post-treatment dose on the CBCT imaging
Time Frame: Until the end of the radiotherapy treatment
|
Calculation of the dose effectively delivered to target volumes and organs at risk, recalculated from pre-treatment CBCT images
|
Until the end of the radiotherapy treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: BOISBOUVIER Sophie, Centre Leon Berard
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ET20-184 - ST-IGRT ORL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on EXATRAC imaging
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingLymphedema of the Head and NeckUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnUnspecified Adult Solid TumorUnited States
-
Hungarian Institute of CardiologyRecruitingAtrial FibrillationHungary
-
Universitaire Ziekenhuizen KU LeuvenUnknownGlaucoma | Posterior Vitreous Detachment | Vitreomacular Traction | Vitreopapillary TractionBelgium
-
M.D. Anderson Cancer CenterCompleted
-
University of Wisconsin, MadisonTerminatedHead and Neck Cancer | Esophageal Cancer | Lung Cancer | Prostate Cancer | CNS Brain MetastasesUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedMRI | Prostate CancerUnited States
-
Stanford UniversityRecruiting
-
University of LeipzigUnknown
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); The Finnish Funding Agency for...CompletedCoronary Artery Disease | Heart Failure | Ischemic CardiomyopathyCanada, Finland, United States, Argentina, Brazil